Long‐term trajectories of cognition, neurodegeneration, and clinical progression in cognitively unimpaired individuals with elevated levels of plasma % p ‐tau217

Abstract

Background: % p ‐tau217 ratio has emerged as a promising plasma biomarker for Alzheimer’s disease (AD) pathology, reaching performance levels comparable to CSF‐based measures. However, its prognostic value in cognitively unimpaired (CU) individuals remains to be further explored.